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ABSTRACT
We have developed high-throughput microtitre
plate-based assays for DNA gyrase and other DNA
topoisomerases. These assays exploit the fact that
negatively supercoiled plasmids form intermole-
cular triplexes more efficiently than when they
are relaxed. Two assays are presented, one using
capture of a plasmid containing a single triplex-
forming sequence by an oligonucleotide tethered to
the surface of a microtitre plate and subsequent
detection by staining with a DNA-specific fluores-
cent dye. The other uses capture of a plasmid
containing two triplex-forming sequences by an
oligonucleotide tethered to the surface of a micro-
titre plate and subsequent detection by a second
oligonucleotide that is radiolabelled. The assays
are shown to be appropriate for assaying DNA
supercoiling by Escherichia coli DNA gyrase and
DNA relaxation by eukaryotic topoisomerases I
and II, and E.coli topoisomerase IV. The assays are
readily adaptable to other enzymes that change
DNA supercoiling (e.g. restriction enzymes) and are
suitable for use in a high-throughput format.
INTRODUCTION
DNA topoisomerases are essential enzymes that control
the topological state of DNA in cells (1,2). In prokaryotes
these enzymes are targets of antibacterial agents, in
eukaryotes they are anti-tumour drug targets and potential
herbicide targets (3–5). All topoisomerases can relax super-
coiled DNA, and DNA gyrase, present in bacteria, can also
introduce supercoils into DNA. Despite being the target of
some of the key antimicrobials and anti-cancer drugs in use
today (e.g. ciproﬂoxacin and camptothecins), their basic reac-
tion, the inter-conversion of relaxed and supercoiled DNA,
is not readily monitored. The standard assay is gel-based
(see e.g. Figure 3), and suffers from the drawback of being
slow and, due to the electrophoresis step, requires a lot of
sample handling. There is a pressing need to develop higher-
throughput assays, which would greatly facilitate work on
topoisomerases (and other enzymes), and speciﬁcally would
potentiate the use of combinatorial chemical libraries to
screen for novel lead compounds (antimicrobials, anti-tumour
drugs and herbicides). To this end we have developed
topoisomerase assays based on DNA triplex formation; the
underlying principle being the greater efﬁciency of triplex
formation in negatively supercoiled DNA compared with
the relaxed form. Using this principle, we have developed
assays where the signal is either radioactivity or ﬂuorescence.
DNA triplexes are alternative structures to the DNA double
helix. In these structures a DNA duplex associates with
another single strand in either a parallel or antiparallel ori-
entation to form the triple-stranded structure (6–9). Triplexes
can be intra- or intermolecular and generally consist of a
polypyrimidine or polypurine strand lying in the major
groove of a DNA duplex. Triplexes are of two basic types:
one purine and two pyrimidine strands (YR*Y), or one
pyrimidine and two purine strands (YR*R), stabilized by
Hoogsteen base pairing. A protonated C forms two hydrogen
bonds to the N7 and O6 of G, or a T forms hydrogen bonds to
the N7 and 6-NH2 groups of A. YR*Y triplexes have a pyr-
imidine third strand bound parallel to the duplex purine strand
(involving T.AT and C
+.GC triplets); YR*R triplexes have a
purine third strand bound antiparallel to the duplex purine
strand (involving G.GC, A.AT and T.AT triplets).
Triplex formation has been used in a variety of applica-
tions, including therapeutic targeting of oligos to speciﬁc
DNA sequences (8). More recently triplexes have been used
as a basis for assays for DNA translocation by type I restric-
tion enzymes (10,11); the principle of these assays is the dis-
placement of a ﬂuorescently-labelled triplex-forming oligo
(TFO) by the translocating enzyme. In other work it has
been shown that triplex formation inhibits DNA gyrase activ-
ity, presumably by blocking access to the DNA duplex (12).
The aspect of DNA triplex formation that we have sought
to exploit is the observation that triplex formation is favoured
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doi:10.1093/nar/gkl504by negative supercoiling (13,14); so far this has only been
reported for intramolecular triplexes, but it is likely to affect
intermolecular triplexes as well. Previously immobilized
biotinylated TFOs have been shown to be able to capture
supercoiled plasmid DNAs (15). Following on from this
work, we have now developed methods for assaying topoi-
somerases and other enzymes based on the differential
capture of negatively supercoiled versus relaxed plamids by
immobilized TFOs.
MATERIALS AND METHODS
Enzymes, DNA and drugs
Escherichia coli DNA gyrase and DNA topoisomerase
(topo) IV were from John Innes Enterprises Ltd (gifts of
Mrs A.J. Howells); DNA topoisomerase I (wheat germ) was
purchased from Promega, human topoisomerase I and II were
from Topogen. Restriction enzymes were purchased from
New England BioLabs (AvaI and AatII) and Invitrogen
(EcoRI). TFOs were purchased from Sigma Genosys and
are listed in Table 1. Plasmid pBR322* [a high copy number
mutant form of plasmid pBR322 (16)] was from John Innes
Enterprises Ltd (gift of Mrs A.J. Howells). To construct
plasmid pNO1, oligos TFO1W and TFO1C (Table 1) were
annealed and ligated into the AvaI site of pBR322*. To con-
struct plasmid pNO11, oligos TFO2W and TFO2C (Table 1)
were annealed and ligated into the AatII site of pNO1. The
sequences of pNO1 and pNO11 were veriﬁed by DNA
sequencing. Supercoiled forms of plasmids were prepared by
transforming them into Top10 competent cells (Invitrogen)
and growing in Luria–Bertani (LB) broth containing ampicil-
lin (Sigma), and preparing the DNA using Qiagen mini and
midi prep kits. Relaxed plasmids were prepared by incubating
the supercoiled forms with topo I [ 40–50 mg plasmid, 200 U
topo I, in 50 mM Tris–HCl (pH 7.5), 50 mM NaCl and
0.1 mM EDTA], for 1 h at 37 C, and were puriﬁed by phenol/
chloroform extraction and ethanol precipitation. Plasmids
with speciﬁc linking difference (s) in the range 0–0.11 were
made by relaxing the supercoiled form with topo I in the pres-
ence of different concentrations of ethidium bromide [100 mg
plasmid, 400 U topo I, in 20 mM Tris–HCl (pH 8.0), 200 mM
NaCl, 0.25 mM EDTA, 5% glycerol plus 0.01 mg/ml BSA],
for 1.5 h at 37 C, and subsequent puriﬁcation by two phenol/
chloroform extractions, one chloroform extraction and
precipitation with ethanol. Plasmids were resuspended in
10 mM Tris–HCl (pH 8.0), 1 mM EDTA. TFO2 was radio-
labelled using polynucleotide kinase and [g-
32P]dATP.
Radiolabelled oligos were separated from unlabelled material
using Microspin G-25 columns (Amersham Biosciences).
Ciproﬂoxacin and novobiocin were purchased from Sigma
and Fluka, respectively; SYBR Gold nucleic acid stain was
purchased from Invitrogen; camptothecin was purchased
from Sigma.
Surface plasmon resonance (SPR)
SPR was carried out using a Biacore X instrument.
Streptavidin-coated chips (SA chip; Biacore International
SA) had  5 ml 100 nM biotinylated oligo (TFO1 or TFO2)
in HBS-EP Buffer (Biacore International SA) immobilized
on to ﬂow cell 2 (giving a response of  250 RU). Plasmids
in TF Buffer [50 mM sodium acetate (pH 5.0), 50 mM NaCl
and 50 mM MgCl2] were injected at a concentration of 4 nM.
The SA chip was regenerated using 50 ml 1 M NaCl in
50 mM NaOH.
Enzyme assays
DNA gyrase supercoiling assays, using gel electrophoresis,
were carried out based on published procedures (17) as fol-
lows. Reactions (30 ml) contained 1 mg relaxed plasmid
DNA, in 35 mM Tris–HCl (pH 7.5), 24 mM KCl, 4 mM
MgCl2, 2 mM DTT, 1.8 mM spermidine, 1 mM ATP, 6.5%
(w/v) glycerol, 0.1 mg/ml albumin (John Innes Enterprises)
and were incubated at 37 C for 30 min. Samples were ana-
lysed either using microplate assays (below) or by electro-
phoresis on 1% agarose gels; results from gel assays were
quantitated using the intensity of the ethidium ﬂuorescence
of the supercoiled DNA band using a Syngene GelDoc
system. Where indicated, ciproﬂoxacin and novobiocin
were also added to assays. Topo I, topo II and topo IV assays
were carried out according to the manufacturer’s instructions
(Promega, Topogen and John Innes Enterprises Ltd) using
1 mg supercoiled plasmid DNA as substrate.
Microplate DNA gyrase supercoiling assay based on one
triplex formation
Black streptavidin-coated 96-well microplates (Pierce) were
re-hydrated using 3 · 200 ml Pierce wash buffer. A total of
100 ml 500 nM biotinylated oligo (TFO1) in Pierce wash buf-
fer was immobilized onto the wells. Excess oligo was washed
off using 3 · 200 ml Pierce wash buffer. Enzyme assays
(30 ml) were carried out as described above using 1 mg
relaxed pNO1 or pNO11 as the substrate. Reactions were
incubated at 37 C for 30 min, and then TF buffer (100 ml)
was added to the wells and incubated at room temperature
for 30 min to allow triplex formation. Any unbound plasmid
was washed off with 3 · 200 ml TF buffer, then 200 ml1 X
SYBR Gold (Invitrogen) in 10 mM Tris–HCl (pH 8.0),
1 mM EDTA was added and allowed to stain for 20 min.
After mixing, ﬂuorescence was read using a SPECTRAmax
Gemini ﬂuorimeter and Softmax Pro Software. In some
experiments 10 ml samples were removed from wells for
gel assays (see above).
Microplate DNA gyrase supercoiling assay based on two
triplex formations
Clear streptavidin-coated 96-well microplates were purchased
from Pierce or BD Biosciences and re-hydrated using the
manufacturer’s recommended procedures. DNA gyrase super-
coiling assays were performed as described above except,
after removing any unbound plasmid with 3 · 200 mlT F
Table 1. Oligonucleotides used in this study
Name Sequence (50–30)5 0 Modification
TFO1 TCTCTCTCTCTCTCTC Biotin
TFO2 TTCTTCTTCTTCTTCT Biotin or
32P
TFO1W TCGGAGAGAGAGAGAGAGAG
TFO1C CCGACTCTCTCTCTCTCTCT
TFO2W AAGAAGAAGAAGAAGAACGT
TFO2C TCTTCTTCTTCTTCTTACGT
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32P-labelled TFO2 in TF Buffer was added
to the wells and incubated at room temperature for 30 min.
Any unbound radiolabelled oligo was washed off using
5 · 200 ml TF buffer. The microplate was then placed on a
Fuji imaging plate in a cassette and left overnight. Radio-
activity was estimated using Fuji Bas 1000 and its software;
samples for gel analysis were taken as above.
RESULTS
Construction of triplex plasmids
To enable speciﬁc capture of plasmids by triplex formation
with immobilized oligos, plasmids containing triplex-forming
sequences were constructed (see Materials and Methods).
Plasmid pNO1 is a modiﬁed form of pBR322* containing a
20 bp insert with triplex-forming potential; pNO11 is a modi-
ﬁed form of pNO1 containing a second 20 bp insert with
triplex-forming potential. The ﬁrst triplex-forming insertion,
in both pNO1 and pNO11, should allow them to be captured
by biotinylated oligo TFO1 (Table 1). The second triplex-
forming insertion, in pNO11, should allow a second triplex
formation with TFO2, which is end-labelled for quantitation.
The pyrimidine-rich TFO1 and TFO2 oligos should form
triplexes in the major groove of the inserted sequences in
pNO1 and pNO11, binding parallel to the purine strand,
forming C
+.GC and T.AT triplets. In control experiments,
we showed that both plasmids (pNO1 and pNO11) can be
relaxed by topo I, and that the relaxed form can be super-
coiled by DNA gyrase (data not shown).
SPR
We used SPR to demonstrate plasmid capture by TFOs and to
optimize conditions for triplex formation. The TFO was ﬁrst
immobilized onto one of two ﬂow cells using a streptavidin-
coated chip and a biotinylated oligo. The plasmid was
then injected over the ﬂow cells. Any bound plasmid was
subsequently washed off to regenerate the chip. In control
experiments we found that plasmids with multiple triplex-
forming inserts were captured less efﬁciently than those
with single inserts (data not shown). When the solution con-
ditions were varied, we found that a metal ion was required
(MgCl2), salt was required (either NaCl or KCl) and that
low pH is optimal (pH  5); the best buffer for triplex forma-
tion was found to be: 50 mM sodium acetate (pH 5.0), 50 mM
NaCl and 50 mM MgCl2 (¼ TF Buffer). Under these
conditions we evaluated the capture of negatively super-
coiled, relaxed and partially supercoiled pNO1 by TFO1
(Figure 1A and B). These experiments showed that super-
coiled pNO1 was efﬁciently captured by comparison with
its relaxed form; partially supercoiled pNO1 (speciﬁc linking
difference  0.03) gave a response approximately mid-way
between the other two forms (see below). In control experi-
ments, we found that supercoiled pBR322*, which has no
triplex-forming inserts, was not captured (data not shown).
We also showed that pNO1 could not be efﬁciently captured
by TFO2 (data not shown).
The second plasmid, pNO11, has two triplex-forming
inserts, which could potentially form triplexes with TFO1
and TFO2; we found in SPR experiments that pNO11 could
be captured by either oligo, although the efﬁciency of capture
by TFO2 was somewhat less than by TFO1 (data not shown).
In both cases the supercoiled form was captured preferen-
tially to the relaxed form. From these data we were able to
conclude that both plasmids, when in a negatively super-
coiled form, could be captured by an oligonucleotide immob-
ilized on a chip; the relaxed forms of the plasmids were not
efﬁciently captured. These observations form the basis of the
assays for topoisomerases, and other enzymes, based on DNA
triplex formation.
Microplate DNA gyrase supercoiling assay based on
single triplex formation
Having observed plasmid capture by triplex formation using
SPR, we transferred these principles to a microplate format.
Biotinylated TFO1 was bound to the streptavidin-coated sur-
face of microtitre plates to which plasmids were applied in
TF Buffer. Any unbound plasmids were subsequently washed
off using the same buffer. The wells were then stained with
the nucleic acid stain SYBR Gold and any ﬂuorescence detec-
ted using a microplate ﬂuorescence spectrometer. Figure 2A
shows the results of such an experiment using pNO1 and
pNO11. As before, the supercoiled form of the plasmids is
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Figure 1. Capture of plasmids by TFOs using detection by SPR. Biotinylated
oligos were immobilized on a strepavidin chip in a Biacore X instrument, and
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capture of different forms of pNO1 by immobilized TFO1: Rel ¼ relaxed,
1/2 SC ¼ partially supercoiled, SC ¼ supercoiled. (B) Histogram of response
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linear pNO1 gave little or no ﬂuorescence signal in the micro-
plate assay and did not interfere with the ﬂuorescence signal
from supercoiled pNO1 (Supplementary Data). Using pNO1
prepared at a range of speciﬁc linking differences (s ¼ 0t o
 0.11), we found that the ﬂuorescence response in the micro-
plate assay was approximately linearly proportional to s in
the range  0.035– 0.10 (Figure 2B). A similar relationship
was found in samples containing mixtures of relaxed and
supercoiled DNA (Supplementary Data). In addition, we
found that the binding of SYBR Gold to DNA did not depend
on s (Supplementary Data), i.e. the ﬂuorescence signal in
the assay reﬂects the efﬁciency of triplex formation on the
microplate.
To investigate the utility of this assay for DNA topoi-
somerases, a DNA gyrase supercoiling assay was carried
out in a microplate format using a range of gyrase concentra-
tions; samples were removed from the wells after incubation
with gyrase for analysis by gel electrophoresis (Figure 3A).
This experiment shows that the conversion of the relaxed
DNA substrate to the supercoiled product is readily detected
by the ﬂuorescence assay and that the ﬂuorescence results
parallel those in the gel assay (Figure 3B and C). In control
experiments we showed that the presence of the oligo TFO1
had no effect on the gyrase supercoiling assay monitored by
gel electrophoresis (Supplementary Data). We also showed
that the presence of TF Buffer prevents the gyrase reaction,
i.e. addition of TF Buffer stops the enzyme reaction
(Supplementary Data).
A key feature of a topoisomerase assay is that it can be
utilized to screen for inhibitors. To illustrate this we carried
out gyrase supercoiling assays in the presence of varying
concentrations of the drugs ciproﬂoxacin and novobiocin
(3); again samples for analysis by gel electrophoresis were
taken in parallel (Figure 4; data for novobiocin not
shown). The data show that the ﬂuorescence assay mirrors
the results in the gel assay and correctly reﬂects the degree
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Figure 3. DNA gyrase supercoiling assay using fluorescence and gel-based
assays. Gyrase assay with relaxed pNO1 as a substrate using the indicated
amounts of enzyme in units. Samples were analysed by gel electrophoresis
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e104 Nucleic Acids Research, 2006, Vol. 34, No. 15 PAGE 4 OF 7of inhibition by the drugs. The IC50 values for the two drugs
differ between the gel assay and the microplate assay; e.g.:
ciproﬂoxacin, gel assay, 0.16 mM; microplate assay, 0.07
mM; novobiocin, gel assay 0.06 mM; microplate assay,
0.003 mM. This can be explained as follows. In the gel
assay the apparent IC50 value is determined as the drug
concentration when the intensity of the supercoiled band is
 50%. However, as the gel is unable to resolve supercoiled
species with s greater that   0.03, signiﬁcant inhibition
will have occurred before any change is apparent on
the gel. Hence the gel assay for inhibition of gyrase super-
coiling will tend to give a higher value than the true IC50.
In contrast, the microplate assay shows the full range of
supercoiling (Figure 2B) and so a more accurate IC50 value
is determined, i.e. the microplate IC50 values will be lower
in this case.
We also carried out relaxation assays using wheat germ
and human topo I, human topo II and E.coli topo IV; in all
cases, we found that the microplate assay was applicable.
Figure 5 shows data for relaxation by topo IV and inhibition
of human topo I by camptothecin. In this case the substrate
(supercoiled DNA) shows high ﬂuorescence and the product
(relaxed DNA), low ﬂuorescence. Again the ﬂuorescence
assays (Figure 5B and D) mirror the results in the gel assays
(Figure 5A and C); the difference in the IC50 values for camp-
tothecin (Figure 5C and D) can be rationalized as above, i.e.
it would be expected that the gel assay would give a lower
value for the IC50 as the intensity of the supercoiled
band would reach 50% before the reaction was inhibited
by half. Note that with all the inhibitors used in this paper,
we found no signiﬁcant effect on triplex formation at
concentrations >IC50s, as judged by observed variations
in ﬂuorescence, which were generally <10% compared with
controls (Supplementary Data).
It is likely that this assay can be adapted for any DNA
topoisomerase; indeed any enzyme that changes the super-
coiling of DNA can be assayed. For example, Figure 6
shows microplate ﬂuorescence assays monitoring the cleav-
age of pNO1 by restriction enzymes. This plasmid contains
sites for EcoRI and AatII but not AvaI; this is reﬂected by
a loss of ﬂuorescence with EcoRI and AatII, but not with
AvaI.
As the most expensive element of this assay is the micro-
plates, we performed control experiments to determine
whether wells can be re-used. Following capture of pNO1
by bound biotinylated TFO1, wells were extensively washed
with Pierce wash buffer and then re-used for triplex capture
up to four times without loss of signal strength (data not
shown).
Microplate DNA gyrase supercoiling assay based on two
triplex formations
The microplate assay based on two triplex formations has
the same principles as described above but requires the
formation of a second triplex to give the signal that there is
a captured plasmid. In this case, we immobilized biotinylated
TFO1 onto streptavidin-coated microplate wells and mon-
itored the capture of pNO11. Following capture, the presence
of bound plasmid was detected using radiolabelled TFO2. In
control experiments we showed that supercoiled pNO11 was
captured more efﬁciently than its relaxed form (Figure 7A);
partially supercoiled pNO11 gave an intermediate signal.
We also showed that triplex formation between TFO2 and
pNO11 is speciﬁc, as supercoiled pNO1 (which does not
contain the second triplex sequence) did not give signiﬁcant
signal (data not shown). A DNA gyrase supercoiling assay,
similar to that in Figure 3, was performed in the microplate
using this method (Figure 7B and C). Again the radioactive
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assay.
DISCUSSION
DNA topoisomerases are excellent targets for a range of anti-
microbial and anti-cancer agents; a major reason for this is
that they form a cleavage complex with DNA, which consti-
tutes a particular vulnerability for cells. However, gel-based
assays for topoisomerase activity in vitro suffer from the
drawback of being work-intensive and intrinsically low-
throughput. We have described two versions of a microplate-
based topoisomerase assay that exploit the differential ability
of negatively supercoiled and relaxed plasmid DNAs to
form intermolecular triplexes. These assays are relatively
inexpensive and are straightforward to perform and will be
of use to those working in the drug-discovery area and
those interested in topoisomerase enzymology. We have
found that for drug-screening purposes, the single triplex
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e104 Nucleic Acids Research, 2006, Vol. 34, No. 15 PAGE 6 OF 7assay is the most convenient as it uses non-radioactive
detection and the formation of a single triplex is more
efﬁcient that the formation of two triplexes.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR online.
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Figure 7. Plasmid capture and supercoiling assay using the two triplex
method. (A) Plasmids captured by TFO1 in the microplate assay and detected
by radiolabelled TFO2. (B and C) Gyrase assay with relaxed pNO11 as the
substrate using the indicated amounts of enzyme. Samples were analysed by
gel electrophoresis (B) and binding of radiolabelled TFO2 (C).
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